What is the value of oncology medicines?

被引:11
作者
Cohen, Joshua [1 ]
Looney, William [2 ]
机构
[1] Tufts Univ, Sch Med, Ctr Study Drug Dev, Boston, MA 02111 USA
[2] Pfizer, New York, NY USA
关键词
OFF-LABEL USE; COST-EFFECTIVENESS; CANCER DRUGS; SURVIVAL; ACCESS; CHALLENGES;
D O I
10.1038/nbt1110-1160
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Coverage with evidence development (CED), rather than quality-adjusted-life-year (QALY) thresholds, offers the best way forward in balancing evidence-based policy for new oncology products with the needs of developers, payers, physicians and patients.
引用
收藏
页码:1160 / 1163
页数:4
相关论文
共 35 条
[1]  
[Anonymous], CDC FASTSTATS
[2]  
[Anonymous], NICE GUIDANCE
[3]   Using Effectiveness and Cost-effectiveness to Make Drug Coverage Decisions A Comparison of Britain, Australia, and Canada [J].
Clement, Fiona M. ;
Harris, Anthony ;
Li, Jing Jing ;
Yong, Karen ;
Lee, Karen M. ;
Manns, Braden J. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2009, 302 (13) :1437-1443
[4]   Preferences, needs and QALYs [J].
Cohen, J .
JOURNAL OF MEDICAL ETHICS, 1996, 22 (05) :267-272
[5]   Comparing Patient Access to Pharmaceuticals in the UK and US [J].
Cohen, Joshua ;
Cairns, Catherine ;
Paquette, Cherie ;
Faden, Laura .
APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2006, 5 (03) :177-187
[6]   New challenges to medicare beneficiary access to mAbs [J].
Cohen, Joshua ;
Wilson, Andrew .
MABS, 2009, 1 (01) :56-66
[7]  
Cohen J, 2009, FOOD DRUG LAW J, V64, P391
[8]   Economics of new oncology drug development [J].
DiMasi, Joseph A. ;
Grabowski, Henry G. .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (02) :209-216
[9]   Trends in the global funding and activity of cancer research [J].
Eckhouse, Seth ;
Lewison, Grant ;
Sullivan, Richard .
MOLECULAR ONCOLOGY, 2008, 2 (01) :20-32
[10]   A survey of public funding of cancer research in the European Union [J].
Eckhouse, Seth ;
Sullivan, Richard .
PLOS MEDICINE, 2006, 3 (07) :994-999